
November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline
November 2021 Top Biopharma Deal Upfront
Owkin discovery and development deal with Sanofi for AI models for cancer
Announced: November 18, 2021
Total Deal Value: $270M + Mst
Upfront Cash: none
Upfront Equity: $180M
R&D Funding: $90M over 3 years
Milestones: undisclosed R&D Mst
Royalty: n/a
Cost and Profit Split: n/a
The Asset:
Owkin’s artificial intelligence and federated learning platform to support digital clinical research in Sanofi’s core oncology efforts in 4 different cancers.
Deal Structure:
R&D Only
Partnership Features:
Collaborative Development, Funded R&D
The Details:
- Owkin will receive a $180M upfront equity investment, $90M in R&D funding over 3 years, and is eligible for additional undisclosed R&D milestones.
- Sanofi will apply Owkin’s artificial intelligence (AI) and federated learning platform to advance its oncology pipeline, which includes non-small cell lung cancer (NSCLC), triple-negative breast cancer, mesothelioma, and multiple myeloma. This research partnership agreement will allow Sanofi to work closely with Owkin to identify new oncology treatments across 4 cancers.
- Sanofi will use the Owkin platform to find new biomarkers and therapeutic targets, build prognostic models, and predict response to treatment from multimodal patient data.
- Owkin’s global research network is powered by federated learning, which allows data scientists to securely connect to decentralized, multi-party data sets to train AI models without having to pool data. This approach will complement Sanofi’s developments oncology.
Last Month:
Congrats to Owkin and Sanofi for landing DealForma’s November 2021 Top Biopharma Deal. Last month’s Deal of the Month was Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Want data for your analysis? Want us to do it? Subscribers get both.
Schedule your demo of the DealForma database to see how we help you get better reports done faster.
25,544
Deal Profiles
15,147
Funding Rounds
28,034
Company Profiles
17,936
Product Profiles
119K+
Clinical Trials
3,982
Business Developers
Specifically for Biotech, Pharma, Device, and Diagnostics
Get more done.
Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.
More Research by DealForma
Oncology Partnering Deal Trends: Early Stage Deals Dominate with Highest Potential Deal Values
Innovative biotech companies are in a stronger position today as far as the value of their assets. We look at oncology deal payments by stage at signing.
Top Investors in Biotech Venture Rounds
Global biotechnology venture investment topped $11.8 billion in 258 financing rounds in the first 10 months of 2018. Who are the top biotech venture investors, where are they investing their money, and what are they investing in?
Biotech Companies in Major Industry Centers Rake in the Cash
Location, Location, Location: Real estate costs a lot in the three largest biotech hubs, but it’s a charm for raising capital. Biotech companies raised $37.4 billion globally in 1027 rounds of venture financing over the past four years from 2015 through the third quarter of 2018 and companies located in the San Francisco Bay Area, greater Boston area, and San Diego County accounted for 55 percent of the total raised and 46 percent of the financing activity.
Top 10 Biopharma Dealmakers by Upfront Cash
Pharma deal upfront cash payments made for development and commercialization with biotech, device, diagnostics, and technology platform companies.
You met on Zoom. Now it's Deal Time.
With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.